NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|160333081|ref|NP_115929|]
View 

kell blood group glycoprotein homolog [Mus musculus]

Protein Classification

M13 family metallopeptidase( domain architecture ID 10171382)

M13 family metallopeptidase similar to neutral endopeptidase (neprilysin), which degrades and inactivates bioactive peptides, and to endothelin-converting enzyme, which catalyzes the hydrolysis of the bond between Trp-21 and Val-22 in big endothelin to form endothelin 1

EC:  3.4.24.-
MEROPS:  M13
SCOP:  3001975

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
78-711 1.53e-169

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


:

Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 501.13  E-value: 1.53e-169
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  78 VAPCTDFFSFAC---EKAN------GTSDSFQALTEENKSRLWRLLEAPGSWHL-GSGEEKAFQFYNSCMDTDAIEASGS 147
Cdd:cd08662    1 VDPCDDFYQYACgnwLKNHpipadkSSWGSFSELQDRNEEQLREILEEAASSAAdSSAEQKAKDFYKSCMDEEAIEKLGL 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 148 GPLIQIIEELGGWNITGNWTsldfNQNLRLLMSQYGHFPFFRAYLRPHPAPPHTPIIQIDQPEFDILLQQEQEQKVYAQI 227
Cdd:cd08662   81 KPLKPLLDKIGGLPSLDDLA----AELLLALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYLDEENAEI 156
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 228 LREYVTYLNRLGTLLGSNPQEAQQHASWSIVFTSRLFQFLRPQQQQQAQDKLFHVVTIDELQEMAPAIDWLSCLQAIFTP 307
Cdd:cd08662  157 REAYKKYIAKLLELLGADEEEAEKLAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLAPSIDWKAYLKALGPP 236
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 308 msLNSSQTLVVHDLDYLRNMSQLVEEgllNHRESIQSYMILGLVDTLSPALDTKFQEARRELIQELRKLKERPPlpaypR 387
Cdd:cd08662  237 --ADDPDKVIVSQPEYLKKLDKLLAS---TPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFYGKALSGQKEPEP-----R 306
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 388 WMKCVEQTGAFFEPTLAALFVREAFGPSIQSAAMELFAEIKDAVIIRLKKLSWISEETQKEALNKLAQLQVEMGAPKRAV 467
Cdd:cd08662  307 WKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLDAMKVKIGYPDKWR 386
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 468 KPDIATQEYNDIQLGPSFLQSFLSCVRSLRARNVQSFLQPFPYHRWQKSPWEVNAYYSISDHMVVFPAGLLQPPFFHPGY 547
Cdd:cd08662  387 DYSALDIYYDDLNVSDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIVFPAGILQPPFFDPDA 466
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 548 PRAVNFGAAGSIMAHELLHIF--------YQLLLPGGCPACDTHVLQEALLCLERHYAAFPLPSISSFNGSHTLLENAAD 619
Cdd:cd08662  467 PDALNYGGIGAVIGHEITHGFddqgrqydENGNLRNWWTNEDRKEFEERAQCLVDQYSNYEVPPGLHVNGKLTLGENIAD 546
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 620 IGGVAIAFQAYSKRIVEHTGELtLPNLDLSPYQLFFRSYAQVMCR-----GLSSQDPQDPHSPPSLRVHGPLSNTPDFAK 694
Cdd:cd08662  547 NGGLRLAYRAYKKWLKENGPEL-PGLEGFTPEQLFFLSFAQVWCSkyrpeALRQLLLTDPHSPGKFRVNGPLSNSPEFAE 625
                        650
                 ....*....|....*..
gi 160333081 695 HFHCPRGTLLNPSARCK 711
Cdd:cd08662  626 AFNCPPGSPMNPEKKCR 642
 
Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
78-711 1.53e-169

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 501.13  E-value: 1.53e-169
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  78 VAPCTDFFSFAC---EKAN------GTSDSFQALTEENKSRLWRLLEAPGSWHL-GSGEEKAFQFYNSCMDTDAIEASGS 147
Cdd:cd08662    1 VDPCDDFYQYACgnwLKNHpipadkSSWGSFSELQDRNEEQLREILEEAASSAAdSSAEQKAKDFYKSCMDEEAIEKLGL 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 148 GPLIQIIEELGGWNITGNWTsldfNQNLRLLMSQYGHFPFFRAYLRPHPAPPHTPIIQIDQPEFDILLQQEQEQKVYAQI 227
Cdd:cd08662   81 KPLKPLLDKIGGLPSLDDLA----AELLLALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYLDEENAEI 156
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 228 LREYVTYLNRLGTLLGSNPQEAQQHASWSIVFTSRLFQFLRPQQQQQAQDKLFHVVTIDELQEMAPAIDWLSCLQAIFTP 307
Cdd:cd08662  157 REAYKKYIAKLLELLGADEEEAEKLAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLAPSIDWKAYLKALGPP 236
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 308 msLNSSQTLVVHDLDYLRNMSQLVEEgllNHRESIQSYMILGLVDTLSPALDTKFQEARRELIQELRKLKERPPlpaypR 387
Cdd:cd08662  237 --ADDPDKVIVSQPEYLKKLDKLLAS---TPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFYGKALSGQKEPEP-----R 306
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 388 WMKCVEQTGAFFEPTLAALFVREAFGPSIQSAAMELFAEIKDAVIIRLKKLSWISEETQKEALNKLAQLQVEMGAPKRAV 467
Cdd:cd08662  307 WKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLDAMKVKIGYPDKWR 386
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 468 KPDIATQEYNDIQLGPSFLQSFLSCVRSLRARNVQSFLQPFPYHRWQKSPWEVNAYYSISDHMVVFPAGLLQPPFFHPGY 547
Cdd:cd08662  387 DYSALDIYYDDLNVSDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIVFPAGILQPPFFDPDA 466
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 548 PRAVNFGAAGSIMAHELLHIF--------YQLLLPGGCPACDTHVLQEALLCLERHYAAFPLPSISSFNGSHTLLENAAD 619
Cdd:cd08662  467 PDALNYGGIGAVIGHEITHGFddqgrqydENGNLRNWWTNEDRKEFEERAQCLVDQYSNYEVPPGLHVNGKLTLGENIAD 546
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 620 IGGVAIAFQAYSKRIVEHTGELtLPNLDLSPYQLFFRSYAQVMCR-----GLSSQDPQDPHSPPSLRVHGPLSNTPDFAK 694
Cdd:cd08662  547 NGGLRLAYRAYKKWLKENGPEL-PGLEGFTPEQLFFLSFAQVWCSkyrpeALRQLLLTDPHSPGKFRVNGPLSNSPEFAE 625
                        650
                 ....*....|....*..
gi 160333081 695 HFHCPRGTLLNPSARCK 711
Cdd:cd08662  626 AFNCPPGSPMNPEKKCR 642
Peptidase_M13_N pfam05649
Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of ...
80-463 8.06e-104

Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of organizms including mammals and bacteria. In mammals they participate in processes such as cardiovascular development, blood-pressure regulation, nervous control of respiration, and regulation of the function of neuropeptides in the central nervous system. In bacteria they may be used for digestion of milk.


Pssm-ID: 461703  Cd Length: 382  Bit Score: 322.33  E-value: 8.06e-104
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081   80 PCTDFFSFAC---EKAN------GTSDSFQALTEENKSRLWRLL-EAPGSWHLGSGEEKAFQFYNSCMDTDAIEASGSGP 149
Cdd:pfam05649   1 PCDDFYQYACggwLKNHpipadkSSWGTFDELRERNEKQLREILeEAAASESDPGAVEKAKDLYKSCMDTDAIEKLGLKP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  150 LIQIIEELGGWNItgNWTSLDFNQNLRLLMSqYGHFPFFRAYLRPHPAPPHTPIIQIDQPEF-----DILLQQEQEQkvY 224
Cdd:pfam05649  81 LKPLLDEIGGPLA--NKDKFDLLETLAKLRR-YGVDSLFGFGVGPDDKNSSRNILYLDQPGLglpdrDYYLKDRDEK--S 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  225 AQILREYVTYLNRLGTLLGSNpQEAQQHASWSIVFTSRLFQFLRPQQQQQAQDKLFHVVTIDELQEMAPAIDWLSCLQAI 304
Cdd:pfam05649 156 AEIREAYKAYIAKLLTLLGAS-EEAAALAEEVLAFETKLAKASLSREERRDPEKTYNPMTLAELQKLAPGIDWKAYLNAA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  305 FTPMslNSSQTLVVHDLDYLRNMSQLVEEgllNHRESIQSYMILGLVDTLSPALDTKFQEARRELIQELRKLKERPplpa 384
Cdd:pfam05649 235 GLPD--VPSDEVIVSQPEYLKALSKLLAE---TPLRTLKNYLIWRLVRSLAPYLSDEFRDANFEFYGTLSGTKQRP---- 305
                         330       340       350       360       370       380       390
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 160333081  385 ypRWMKCVEQTGAFFEPTLAALFVREAFGPSIQSAAMELFAEIKDAVIIRLKKLSWISEETQKEALNKLAQLQVEMGAP 463
Cdd:pfam05649 306 --RWKRCVSLVNGLLGEALGRLYVKKYFPEEAKARVEELVENIKEAFRERLDELDWMDEETKKKALEKLDAMTVKIGYP 382
PepO COG3590
Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];
71-713 4.69e-96

Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];


Pssm-ID: 442809 [Multi-domain]  Cd Length: 674  Bit Score: 311.32  E-value: 4.69e-96
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  71 LASGNRSVAPCTDFFSFACEK--------ANGTSD-SFQALTEENKSRLWRLLE--APGSWHLGSGEEKAFQFYNSCMDT 139
Cdd:COG3590   30 LANMDTSVRPGDDFYRYVNGGwlkttpipADRSRWgSFNELRERNEARLRAILEeaAAAPAAAGSDEQKIGDLYASFMDE 109
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 140 DAIEASGSGPLIQIIEELGGwnITgnwtslDFNQNLRLL--MSQYGHFPFFRAYLRPHPAPPHTPIIQIDQ-----PEFD 212
Cdd:COG3590  110 AAIEALGLAPLKPDLARIDA--IK------DKADLAALLaaLHRAGVGGLFGFGVDADLKNSTRYIAYLGQgglglPDRD 181
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 213 ILLQQEQEqkvYAQILREYVTYLNRLGTLLGSNPQEAQQHA-------------SWSIVfTSRlfqflrpqqqqqAQDKL 279
Cdd:COG3590  182 YYLKDDEK---SAEIRAAYVAHVAKMLELAGYDEADAAAAAeavlaletalakaHWSRV-ELR------------DPEKT 245
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 280 FHVVTIDELQEMAPAIDWlsclQAIFTPMSLNSSQTLVVHDLDYLRNMSQLVEEGLLnhrESIQSYMILGLVDTLSPALD 359
Cdd:COG3590  246 YNPMTVAELAKLAPGFDW----DAYLKALGLPAVDEVIVGQPSFFKALDKLLASTPL---EDWKAYLRWHLLDSAAPYLS 318
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 360 TKFQEAR-----REL--IQELRklkerpplpayPRWMKCVEQTGAFFEPTLAALFVREAFGPSIQSAAMELFAEIKDAVI 432
Cdd:COG3590  319 KAFVDANfdfygKTLsgQKEQR-----------PRWKRAVALVNGALGEALGQLYVERYFPPEAKARMEELVANLRAAYR 387
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 433 IRLKKLSWISEETQKEALNKLAQLQVEMGAPKRAvkpdiatQEYNDIQLGP-SFLQSFLSCVRSLRARNVQSFLQPFPYH 511
Cdd:COG3590  388 ERIENLDWMSPETKAKALEKLAAFTPKIGYPDKW-------RDYSGLEIKRdDLVGNVLRASAFEYQRELAKLGKPVDRT 460
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 512 RWQKSPWEVNAYYSISDHMVVFPAGLLQPPFFHPGYPRAVNFGAAGSIMAHELLHIFyqlllpggcpacDThvlQ----- 586
Cdd:COG3590  461 EWGMTPQTVNAYYNPTMNEIVFPAAILQPPFFDPKADDAVNYGGIGAVIGHEITHGF------------DD---Qgsqfd 525
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 587 -----------------EALL-CLERHYAAF-PLPSIsSFNGSHTLLENAADIGGVAIAFQAYSKriveHTGELTLPNLD 647
Cdd:COG3590  526 gdgnlrnwwtpedraafEARTkKLVAQYDAYePLPGL-HVNGKLTLGENIADLGGLSIAYDAYKL----SLKGKEAPVID 600
                        650       660       670       680       690       700       710
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 160333081 648 -LSPYQLFFRSYAQVMCrglSSQDPQ--------DPHSPPSLRVHGPLSNTPDFAKHFHCPRGT--LLNPSARCKLW 713
Cdd:COG3590  601 gFTGDQRFFLGWAQVWR---SKARDEalrqrlatDPHSPGEFRVNGPVRNLDAFYEAFDVKPGDkmYLAPEDRVRIW 674
 
Name Accession Description Interval E-value
M13 cd08662
Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of ...
78-711 1.53e-169

Peptidase family M13 includes neprilysin and endothelin-converting enzyme I; The M13 family of metallopeptidases includes neprilysin (neutral endopeptidase, NEP, enkephalinase, CD10, CALLA, EC 3.4.24.11), endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), erythrocyte surface antigen KELL (ECE-3), phosphate-regulating gene on the X chromosome (PHEX), soluble secreted endopeptidase (SEP), and damage-induced neuronal endopeptidase (DINE)/X-converting enzyme (XCE). Proteins in this family fulfill a broad range of physiological roles due to the greater variation in the active site's S2' subsite allowing substrate specificity. NEP is expressed in a variety of tissues including kidney and brain, and is involved in many physiological and pathological processes, including blood pressure and inflammatory response. It degrades a wide array of substrates such as substance P, enkephalins, cholecystokinin, neurotensin and somatostatin. It is an important enzyme in the regulation of amyloid-beta (Abeta) protein that forms amyloid plaques that are associated with Alzeimers disease (AD). ECE-1 catalyzes the final rate-limiting step in the biosynthesis of endothelins via post-translational conversion of the biologically inactive big endothelins. Like NEP, it also hydrolyzes bradykinin, substance P, neurotensin, and Abeta. Endothelin-1 overproduction has been implicated in various diseases including stroke, asthma, hypertension, and cardiac and renal failure. Kell is a homolog of NEP and constitutes a major antigen on human erythrocytes; it preferentially cleaves big endothelin-3 to produce bioactive endothelin-3, but is also known to cleave substance P and neurokinin A. PHEX forms a complex interaction with fibroblast growth factor 23 (FGF23) and matrix extracellular phosphoglycoprotein, causing bone mineralization. A loss-of-function mutation in PHEX disrupts this interaction leading to hypophosphatemic rickets; X-linked hypophosphatemic (XLH) rickets is the most common form of metabolic rickets. ECEL1 is a brain metalloprotease which plays a critical role in the nervous regulation of the respiratory system, while DINE is abundantly expressed in the hypothalamus and its expression responds to nerve injury. A majority of these M13 proteases are prime therapeutic targets for selective inhibition.


Pssm-ID: 341056 [Multi-domain]  Cd Length: 642  Bit Score: 501.13  E-value: 1.53e-169
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  78 VAPCTDFFSFAC---EKAN------GTSDSFQALTEENKSRLWRLLEAPGSWHL-GSGEEKAFQFYNSCMDTDAIEASGS 147
Cdd:cd08662    1 VDPCDDFYQYACgnwLKNHpipadkSSWGSFSELQDRNEEQLREILEEAASSAAdSSAEQKAKDFYKSCMDEEAIEKLGL 80
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 148 GPLIQIIEELGGWNITGNWTsldfNQNLRLLMSQYGHFPFFRAYLRPHPAPPHTPIIQIDQPEFDILLQQEQEQKVYAQI 227
Cdd:cd08662   81 KPLKPLLDKIGGLPSLDDLA----AELLLALLRRLGVSLLFGLGVSPDPKNSSRNILYLGQPGLGLPDRDYYLDEENAEI 156
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 228 LREYVTYLNRLGTLLGSNPQEAQQHASWSIVFTSRLFQFLRPQQQQQAQDKLFHVVTIDELQEMAPAIDWLSCLQAIFTP 307
Cdd:cd08662  157 REAYKKYIAKLLELLGADEEEAEKLAEDVLAFETELAKISLSSEELRDPEKTYNPLTLAELQKLAPSIDWKAYLKALGPP 236
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 308 msLNSSQTLVVHDLDYLRNMSQLVEEgllNHRESIQSYMILGLVDTLSPALDTKFQEARRELIQELRKLKERPPlpaypR 387
Cdd:cd08662  237 --ADDPDKVIVSQPEYLKKLDKLLAS---TPLRTLKNYLIWRLLDSLAPYLSKEFRDARFFYGKALSGQKEPEP-----R 306
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 388 WMKCVEQTGAFFEPTLAALFVREAFGPSIQSAAMELFAEIKDAVIIRLKKLSWISEETQKEALNKLAQLQVEMGAPKRAV 467
Cdd:cd08662  307 WKRCVELVNGALGEALGRLYVEKYFSEEAKADVEEMVENIKEAFKERLENLDWMDEETKKKALEKLDAMKVKIGYPDKWR 386
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 468 KPDIATQEYNDIQLGPSFLQSFLSCVRSLRARNVQSFLQPFPYHRWQKSPWEVNAYYSISDHMVVFPAGLLQPPFFHPGY 547
Cdd:cd08662  387 DYSALDIYYDDLNVSDSYFENVLRLLRFETKRQLAKLGKPVDRTEWSMSPQTVNAYYNPSLNEIVFPAGILQPPFFDPDA 466
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 548 PRAVNFGAAGSIMAHELLHIF--------YQLLLPGGCPACDTHVLQEALLCLERHYAAFPLPSISSFNGSHTLLENAAD 619
Cdd:cd08662  467 PDALNYGGIGAVIGHEITHGFddqgrqydENGNLRNWWTNEDRKEFEERAQCLVDQYSNYEVPPGLHVNGKLTLGENIAD 546
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 620 IGGVAIAFQAYSKRIVEHTGELtLPNLDLSPYQLFFRSYAQVMCR-----GLSSQDPQDPHSPPSLRVHGPLSNTPDFAK 694
Cdd:cd08662  547 NGGLRLAYRAYKKWLKENGPEL-PGLEGFTPEQLFFLSFAQVWCSkyrpeALRQLLLTDPHSPGKFRVNGPLSNSPEFAE 625
                        650
                 ....*....|....*..
gi 160333081 695 HFHCPRGTLLNPSARCK 711
Cdd:cd08662  626 AFNCPPGSPMNPEKKCR 642
Peptidase_M13_N pfam05649
Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of ...
80-463 8.06e-104

Peptidase family M13; M13 peptidases are well-studied proteases found in a wide range of organizms including mammals and bacteria. In mammals they participate in processes such as cardiovascular development, blood-pressure regulation, nervous control of respiration, and regulation of the function of neuropeptides in the central nervous system. In bacteria they may be used for digestion of milk.


Pssm-ID: 461703  Cd Length: 382  Bit Score: 322.33  E-value: 8.06e-104
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081   80 PCTDFFSFAC---EKAN------GTSDSFQALTEENKSRLWRLL-EAPGSWHLGSGEEKAFQFYNSCMDTDAIEASGSGP 149
Cdd:pfam05649   1 PCDDFYQYACggwLKNHpipadkSSWGTFDELRERNEKQLREILeEAAASESDPGAVEKAKDLYKSCMDTDAIEKLGLKP 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  150 LIQIIEELGGWNItgNWTSLDFNQNLRLLMSqYGHFPFFRAYLRPHPAPPHTPIIQIDQPEF-----DILLQQEQEQkvY 224
Cdd:pfam05649  81 LKPLLDEIGGPLA--NKDKFDLLETLAKLRR-YGVDSLFGFGVGPDDKNSSRNILYLDQPGLglpdrDYYLKDRDEK--S 155
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  225 AQILREYVTYLNRLGTLLGSNpQEAQQHASWSIVFTSRLFQFLRPQQQQQAQDKLFHVVTIDELQEMAPAIDWLSCLQAI 304
Cdd:pfam05649 156 AEIREAYKAYIAKLLTLLGAS-EEAAALAEEVLAFETKLAKASLSREERRDPEKTYNPMTLAELQKLAPGIDWKAYLNAA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  305 FTPMslNSSQTLVVHDLDYLRNMSQLVEEgllNHRESIQSYMILGLVDTLSPALDTKFQEARRELIQELRKLKERPplpa 384
Cdd:pfam05649 235 GLPD--VPSDEVIVSQPEYLKALSKLLAE---TPLRTLKNYLIWRLVRSLAPYLSDEFRDANFEFYGTLSGTKQRP---- 305
                         330       340       350       360       370       380       390
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 160333081  385 ypRWMKCVEQTGAFFEPTLAALFVREAFGPSIQSAAMELFAEIKDAVIIRLKKLSWISEETQKEALNKLAQLQVEMGAP 463
Cdd:pfam05649 306 --RWKRCVSLVNGLLGEALGRLYVKKYFPEEAKARVEELVENIKEAFRERLDELDWMDEETKKKALEKLDAMTVKIGYP 382
PepO COG3590
Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];
71-713 4.69e-96

Predicted metalloendopeptidase [Posttranslational modification, protein turnover, chaperones];


Pssm-ID: 442809 [Multi-domain]  Cd Length: 674  Bit Score: 311.32  E-value: 4.69e-96
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  71 LASGNRSVAPCTDFFSFACEK--------ANGTSD-SFQALTEENKSRLWRLLE--APGSWHLGSGEEKAFQFYNSCMDT 139
Cdd:COG3590   30 LANMDTSVRPGDDFYRYVNGGwlkttpipADRSRWgSFNELRERNEARLRAILEeaAAAPAAAGSDEQKIGDLYASFMDE 109
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 140 DAIEASGSGPLIQIIEELGGwnITgnwtslDFNQNLRLL--MSQYGHFPFFRAYLRPHPAPPHTPIIQIDQ-----PEFD 212
Cdd:COG3590  110 AAIEALGLAPLKPDLARIDA--IK------DKADLAALLaaLHRAGVGGLFGFGVDADLKNSTRYIAYLGQgglglPDRD 181
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 213 ILLQQEQEqkvYAQILREYVTYLNRLGTLLGSNPQEAQQHA-------------SWSIVfTSRlfqflrpqqqqqAQDKL 279
Cdd:COG3590  182 YYLKDDEK---SAEIRAAYVAHVAKMLELAGYDEADAAAAAeavlaletalakaHWSRV-ELR------------DPEKT 245
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 280 FHVVTIDELQEMAPAIDWlsclQAIFTPMSLNSSQTLVVHDLDYLRNMSQLVEEGLLnhrESIQSYMILGLVDTLSPALD 359
Cdd:COG3590  246 YNPMTVAELAKLAPGFDW----DAYLKALGLPAVDEVIVGQPSFFKALDKLLASTPL---EDWKAYLRWHLLDSAAPYLS 318
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 360 TKFQEAR-----REL--IQELRklkerpplpayPRWMKCVEQTGAFFEPTLAALFVREAFGPSIQSAAMELFAEIKDAVI 432
Cdd:COG3590  319 KAFVDANfdfygKTLsgQKEQR-----------PRWKRAVALVNGALGEALGQLYVERYFPPEAKARMEELVANLRAAYR 387
                        410       420       430       440       450       460       470       480
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 433 IRLKKLSWISEETQKEALNKLAQLQVEMGAPKRAvkpdiatQEYNDIQLGP-SFLQSFLSCVRSLRARNVQSFLQPFPYH 511
Cdd:COG3590  388 ERIENLDWMSPETKAKALEKLAAFTPKIGYPDKW-------RDYSGLEIKRdDLVGNVLRASAFEYQRELAKLGKPVDRT 460
                        490       500       510       520       530       540       550       560
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 512 RWQKSPWEVNAYYSISDHMVVFPAGLLQPPFFHPGYPRAVNFGAAGSIMAHELLHIFyqlllpggcpacDThvlQ----- 586
Cdd:COG3590  461 EWGMTPQTVNAYYNPTMNEIVFPAAILQPPFFDPKADDAVNYGGIGAVIGHEITHGF------------DD---Qgsqfd 525
                        570       580       590       600       610       620       630       640
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081 587 -----------------EALL-CLERHYAAF-PLPSIsSFNGSHTLLENAADIGGVAIAFQAYSKriveHTGELTLPNLD 647
Cdd:COG3590  526 gdgnlrnwwtpedraafEARTkKLVAQYDAYePLPGL-HVNGKLTLGENIADLGGLSIAYDAYKL----SLKGKEAPVID 600
                        650       660       670       680       690       700       710
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 160333081 648 -LSPYQLFFRSYAQVMCrglSSQDPQ--------DPHSPPSLRVHGPLSNTPDFAKHFHCPRGT--LLNPSARCKLW 713
Cdd:COG3590  601 gFTGDQRFFLGWAQVWR---SKARDEalrqrlatDPHSPGEFRVNGPVRNLDAFYEAFDVKPGDkmYLAPEDRVRIW 674
Peptidase_M13 pfam01431
Peptidase family M13; Mammalian enzymes are typically type-II membrane anchored enzymes which ...
521-712 2.15e-71

Peptidase family M13; Mammalian enzymes are typically type-II membrane anchored enzymes which are known, or believed to activate or inactivate oligopeptide (pro)-hormones such as opioid peptides. The family also contains a bacterial member believed to be involved with milk protein cleavage.


Pssm-ID: 279739 [Multi-domain]  Cd Length: 205  Bit Score: 231.15  E-value: 2.15e-71
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  521 NAYYSISDHMVVFPAGLLQPPFFHPGYPRAVNFGAAGSIMAHELLHIFYQLLLP--------GGCPACDTHVLQEALLCL 592
Cdd:pfam01431   1 NAYYQPNRNEIVFPAAILQPPFFDPNYPRAVNYGGIGNVIAHEITHGFDDQGAQfdkdgnlrSWWTDEDAEEFKDRAQCL 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 160333081  593 ERHYAAFPLPS-ISSFNGSHTLLENAADIGGVAIAFQAYSKRivEHTGELTLPNLD-LSPYQLFFRSYAQVMCRGLSSQD 670
Cdd:pfam01431  81 IEQYSEYTPPDgTKCANGTLTLGENIADLGGLTIALRAYKKL--LSANETVLPGFEnLTPDQLFFRGAAQIWCMKQSPAE 158
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|....*..
gi 160333081  671 -----PQDPHSPPSLRVHGPLSNTPDFAKHFHCPRGTLLNPSARCKL 712
Cdd:pfam01431 159 vlrqlLVDPHSPPEFRVNGVMSNMPAFYEAFNCPEGDKMNPEPRCRL 205
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH